We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Simcyp Further Enhances the Drug-Drug Interaction Capabilities of its Flagship Simulator
Product News

Simcyp Further Enhances the Drug-Drug Interaction Capabilities of its Flagship Simulator

Simcyp Further Enhances the Drug-Drug Interaction Capabilities of its Flagship Simulator
Product News

Simcyp Further Enhances the Drug-Drug Interaction Capabilities of its Flagship Simulator


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Simcyp Further Enhances the Drug-Drug Interaction Capabilities of its Flagship Simulator"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Simcyp Limited announces that it has released the latest version of its flagship simulator, further cementing its position as the industry leader in modelling and simulation of drug-drug interactions (DDIs) in virtual populations.

The enhanced features in Version 10.0 of the Simcyp Population-based ADME Simulator have been implemented in accordance with the priorities set by the leading pharmaceutical companies which make up the Simcyp Consortium.

The new developments expand Simcyp’s DDI capabilities to include transporter interactions and provide the flexibility to use clinical inputs in DDI predictions. This is in line with many of the recent regulatory recommendations from the European Medicines Agency (EMA) and the US FDA.  

The Simcyp team has also extended the Advanced Dissolution, Absorption and Metabolism (ADAM) model to allow users to investigate the influence of different drug release formulations or dissolution profiles on the level of DDIs along the gut. This provides more mechanistic and informative predictions.

Commenting on the release, Professor Amin Rostami-Hodjegan, Director of Scientific Research and Development at Simcyp Limited, said: ”The Simcyp Simulator can already handle complex scenarios such as simultaneous competitive inhibition, mechanism-based inhibition and induction of CYP enzymes – the implementation of a competitive inhibitory function for transporters in both the liver and gut provides yet another advanced tool for pharmaceutical researchers and fulfils a specialist niche that is currently a major focus for both industry and the regulators.”

Dr Steve Toon, Executive Director at Simcyp, commented: “For the best part of a decade, the Consortium has guided Simcyp’s world-class research and development, not only in the field of DDIs but also in other key areas, which has resulted in an extremely sophisticated platform that is years ahead of the competition. The Consortium model goes from strength-to-strength and we continue to invest heavily in R&D to satisfy the demands of this fast developing market.”

The Simcyp Simulator is licensed to Consortium members as well as regulatory bodies and eligible academic institutes.
Advertisement